Docoh
Loading...

LCTX Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

Company profile

Ticker
LCTX
Exchange
CEO
Brian Culley
Employees
Incorporated
Location
Fiscal year end
Former names
BIOTIME INC
SEC CIK
IRS number
943127919

LCTX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Mar 21
21 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 32.59M 32.59M 32.59M 32.59M 32.59M 32.59M
Cash burn (monthly) (positive/no burn) (positive/no burn) 1.96M 2.4M 1.88M 1.65M
Cash used (since last report) n/a n/a 7.26M 8.88M 6.96M 6.09M
Cash remaining n/a n/a 25.33M 23.7M 25.62M 26.49M
Runway (months of cash) n/a n/a 12.9 9.9 13.6 16.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Mar 21 Culley Brian M Common Shares, no par value Payment of exercise Dispose F No No 2.35 5,343 12.56K 195,709
31 Mar 21 Culley Brian M Common Shares, no par value Option exercise Aquire M No No 2.35 15,450 36.31K 201,052
31 Mar 21 Culley Brian M RSU Common Shares Option exercise Dispose M No No 0 15,450 0 77,250
30 Mar 21 Alexandra Hernandez Common Shares, no par value Sell Dispose S No No 2.23 6,000 13.38K 0
30 Mar 21 Alexandra Hernandez Common Shares, no par value Option exercise Aquire M No No 0.6919 6,000 4.15K 6,000
30 Mar 21 Alexandra Hernandez Employee Stock Option Common Shares Option exercise Dispose M No No 0.6919 6,000 4.15K 39,200
15 Mar 21 Culley Brian M Employee Stock Option Common Shares Grant Aquire A No No 2.43 1,165,100 2.83M 1,165,100
15 Mar 21 Hogge Gary S. Employee Stock Option Common Shares Grant Aquire A No No 2.43 419,500 1.02M 419,500
15 Mar 21 Leavitt Chase C. Employee Stock Option Common Shares Grant Aquire A No No 2.43 699,100 1.7M 699,100
15 Mar 21 Alexandra Hernandez Employee Stock Option Common Shares Grant Aquire A No No 2.43 42,700 103.76K 42,700

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

34.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 87 0 NEW
Opened positions 87 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 98.65M 0 NEW
Total shares 55.06M 0 NEW
Total puts 26.5K 0 NEW
Total calls 528.3K 0 NEW
Total put/call ratio 0.1
Largest owners
Shares Value Change
Broadwood Capital 34.01M $59.85M NEW
Vanguard 6.21M $10.93M NEW
Defender Capital 4.74M $8.34M NEW
Prescott General Partners 1.85M $3.26M NEW
BLK Blackrock 1.6M $2.82M NEW
Geode Capital Management 1.07M $1.87M NEW
ExodusPoint Capital Management 807.61K $1.42M NEW
Bridgeway Capital Management 680.84K $1.2M NEW
Two Sigma Investments 547.22K $963K NEW
Two Sigma Advisers 509.87K $897K NEW
Largest transactions
Shares Bought/sold Change
Broadwood Capital 34.01M +34.01M NEW
Vanguard 6.21M +6.21M NEW
Defender Capital 4.74M +4.74M NEW
Prescott General Partners 1.85M +1.85M NEW
BLK Blackrock 1.6M +1.6M NEW
Geode Capital Management 1.07M +1.07M NEW
ExodusPoint Capital Management 807.61K +807.61K NEW
Bridgeway Capital Management 680.84K +680.84K NEW
Two Sigma Investments 547.22K +547.22K NEW
Two Sigma Advisers 509.87K +509.87K NEW
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: AAO, Abeona, ACOR, Acorda, adjacent, admitted, advice, advisor, Aeglea, Analyst, Anderson, anesthesiologist, annuity, answer, Aravive, Asia, AstraZeneca, ATM, Atreca, atrophic, attending, attorney, AZN, bailey, banker, Barbara, Bellicum, beneficiary, Bernardino, biochemistry, biographical, biosimilar, Biotie, BITI, Boston, boundary, Brandi, Brisbane, CAA, Calithera, CamberView, career, Carlson, carryover, Celldex, Ceplene, CFA, chair, Chartered, Chase, Chimerix, Citigroup, CMRO, COBRA, Colorado, column, Comarco, concert, continuum, Cornell, corroborated, coupon, Coventry, COVID, Crohn, CTOA, Deborah, delegate, Deputy, Diego, dihydrochloride, diligence, disallowed, discretionary, Doctor, don, Drexel, duly, dying, Edward, effectuated, Elan, exacerbation, Exit, expert, Farrell, Fate, Finland, Floor, footprint, forgivable, forgiven, furlough, Gary, Genocea, Greenbelt, Greenway, Harpoon, headquartered, hearing, histamine, Hogge, honorary, hTERT, hypothesized, Icahn, ICI, Idera, ILS, immunology, Immusol, inevitably, Infinity, inflammatory, Inovio, InterMune, intimate, irreversible, ITMN, Johnson, Lampe, Latham, Leavitt, LLM, loan, logistical, Lynch, magnitude, Magtrol, Mallinckrodt, Marsh, Mast, McLennan, mechanical, Merrill, Mersana, microenvironment, MNK, motion, MSTX, mulroy, natalizumab, nationwide, NBIX, Neon, Neurocrine, NewLink, nominating, nurse, occupy, Odonate, ODT, Orange, Orphagen, outlined, outperformed, paragraph, paused, Paycheck, pecuniary, peer, pension, Pepperdine, PJT, plc, PPP, PPV, predominately, printing, prolonged, QCOR, QIMR, Queensland, Questcor, ratify, Rauth, resignation, resigned, restarted, Revance, RHHBY, risky, Robert, Roche, russell, RVNC, salary, Santa, Savara, SBA, Secretary, setback, shelter, Shire, SHPG, shut, shutdown, signature, simple, Southern, Spero, STAA, STAAR, stipend, Stradling, survey, SVRA, SWCH, Switch, Syndax, Synlogic, Tang, tenure, thereunto, tie, TM, transformed, TSR, Turku, twelfth, TXMD, Tysabri, UCI, UCSD, undersigned, UNITY, unprecedented, unspent, untreated, usability, user, ventilator, wealth, Wharton, Wirth, Yocca, Zeneca, Ziopharm
Removed: advertisement, aesthetic, analyzing, Ascendance, assay, assumption, attestation, attribution, avoiding, background, bankruptcy, biocompatibility, biopsy, brown, Bulletin, caption, chemistry, Coast, collectability, confirmatory, Conversely, core, COSO, deconsolidation, distributed, DNA, doubtful, earliest, endpoint, exclusively, expensing, expired, expiry, feeling, flat, forfeiture, Francisco, gelatin, generating, heart, HIV, hyaluronate, IIB, immaterial, impacting, imposing, induced, inInternal, input, internally, ISO, iTR, lab, lapse, LifeMap, lowering, mimic, muscle, obtainable, offshore, opening, orin, otherin, plasma, PMA, Premvia, prepare, principle, prosecuting, prospective, PureStem®progenitor, ratification, reacquisition, remeasured, renew, repatriation, repealing, SAB, Selection, sodium, specification, straight, sublicense, sublicensed, sublicensee, supplier, telomere, tendon, territorial, Teva, thereon, thiol, unadjusted, unaffiliated, underStaff, underwritten, unilaterally, unique, unqualified, utilizing, vascular, veterinary, waive

Patents

APP
Utility
Methods for Telomere Length and Genomic Dna Quality Control Analysis In Pluripotent Stem Cells
8 Apr 21
The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells.
GRANT
Utility
Methods of screening embryonic progenitor cell lines
16 Feb 21
Aspects of the present invention include methods and compositions related to the production and use of numerous clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells with diverse molecular markers and having been cultured for >21 doublings of clonal expansion.
APP
Utility
Retinal Pigment Epithelium Cell Compositions
6 Jan 21
Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries.
GRANT
Utility
Methods and formulations for orthopedic cell therapy
14 Dec 20
Aspects of the present invention include methods and compositions related to the production and use of clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells, in particular, said methods and compositions relate to methods of differentiating cells in the presence of members of the BMP family of growth factors and the applications of said cell lines in the treatment of degenerative orthopedic diseases such as osteoarthritis.
GRANT
Utility
Methods for telomere length and genomic DNA quality control analysis in pluripotent stem cells
17 Aug 20
The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells.